Mice were inoculated intracerebrally with a lethal dose of herpes simplex virus type 2. Three days later, the mice were treated intraperitoneally, twice daily for 4 days, with the following drugs alone or in combination: acyclovir (ACV), vidarabine (ara-A), 2'-fluoro-5-iodoaracytosine (FIAC), and 2'-fluoro-5-methylarauracil (FMAU). Despite delayed treatment, most of the animals receiving low doses of FMAU alone or in combination with ACV or ara-A survived. In contrast, significantly higher mortality rates were noted in mice receiving ara-A, ACV, or FIAC alone. The data were analyzed for quantitation of synergism, additivity, and antagonism of multiple drug effect by the median effect method. The median effective doses (in nanomoles per kilogram per day) calculated in this manner were: FMAU, 22.5; FIAC, 510; ara-A, 901; ACV, 7,587; ACV-ara-A (drug ratio, 1:1), 550; FIAC-ara-A (1:1), 376; FIAC-ACV (1:1), 133; FMAU-ACV (1:8), 60.3; and FMAU-ara-A (1:8), 65.2. Marked synergy was found throughout a wide range of effect levels with the five different combinations, with no increased toxicity over the single-drug treatments. Similar results were obtained when the data were analyzed by the isobologram method. Since many patients with severe herpetic infections, such as herpes encephalitis, have a poor prognosis despite single-drug therapy, the possible use of combinations including low doses of FMAU deserves further investigation.
Animal models have been useful in providing leads to antiviral drugs for the treatment of herpes simplex virus (HSV) infections. The finding that drugs like vidarabine (ara-A) and acyclovir (ACV) are effective in animal models for HSV encephalitis (14, 19) was later confirmed in humans with the same disease (26, (31) (32) (33) . Nevertheless, beyond the neonatal stage, patients who are comatose when antiviral drugs are administered still do very poorly irrespective of the drug used (26, (31) (32) (33) . Newer approaches are therefore necessary and may include combinations of drugs. We have studied several licensed and experimental drugs which could be candidates for this purpose. Based on animal studies with ara-A, ACV, several 2'-fluoroarabinosyl pyrimidine nucleosides, including 2'-fluoro-5-methylarabinosyluracil (FMAU) and 2'-fluoro-5-iodoarabinosylcytosine (FIAC) (10, 20, 22) , and congeners of acyclovir, such as 9-[(2,3-dihydroxypropoxy)methyl]guanine (DHPG; also known as 2'-NDG, BIOLF-62, and BW759) (27) and buciclovir (9; unpublished data), we concluded that FMAU was the best candidate to be evaluated in humans with severe herpetic infection (20) .
Several reports have demonstrated additive to synergistic effects with various combinations of ACV, ara-A, FIAC, and FMAU when treatment of HSV-infected mice was initiated within 48 h after virus inoculation (7, 13, 17, 22, 23 ; M. R. Karim, S. Bearney, D. E. Foster, C. Lopez, and K. A. Watanabe, Annu. Meet. Am. Soc. Microbiol. 1985, A39, p. 7). To mimic more closely the problem of severe human HSV encephalitis, it appeared to be necessary to evaluate these drugs alone and in combination by delaying treatment for several days after virus inoculation. With experimentally induced HSV encephalitis in mice, the combinations that Laboratories, McLean, Va. The plaque-purified G strain of HSV-2 was supplied by B. Roizman, University of Chicago (8) ; high-titered pools were prepared as described elsewhere (23) .
Infection of mice. Random-bred Swiss ICR mice (female, 5 to 6 weeks old), obtained from Harlan-Sprague Co., Indianapolis, Ind., were acclimatized in the laboratory for 2 weeks. They then received inoculations into the right cerebral hemisphere under anesthesia (Metofane; Pitman-Moore Co., Washington Crossing, N.J.) with strain G of HSV-2. The virus (20 PFU, equivalent to about five 50% lethal doses [LD50]) caused a mortality rate of over 95% in animals treated with PBS. The virus titer of the inoculum was determined in Vero cells by plaque assay (23) . Control animals were inoculated intracerebrally with PBS (0.05 ml). The reasons for selecting this virus strain for the animal studies have been discussed previously (22, 23) .
Drug treatment. Mice were inoculated intracerebrally at about 5 p.m. and treated with drug 72 h later. Recipients were randomized to receive drug or PBS after virus inoculation. The drug solutions were injected in 0.5-ml doses intraperitoneally twice daily at 9 a.m. and 5 p.m. for 4 days, for a total of eight doses. For the combined treatments, the drugs were administered intraperitoneally with separate syringes, with minimum delay between the two doses. The dose ranged from 1.9 to 600 nmol/kg per day (see Table 1 , footnote b, for conversion to milligram-per-kilogram equivalents), and was selected on the basis of delayed treatment results obtained with FMAU, FIAC, and ACV in a previous study (22) . For most of the studies described in this report, a ratio of 1:1 was selected for combinations of ACV and ara-A, ACV and FIAC, and ara-A and FIAC. Because FMAU had been shown to be extremely effective when treatment was delayed, and since the levels of FMAU in the brain of mice are about 14-fold higher than the levels reported for acyclovir (22) axis at y = log (f,Ifj) = 0 will give the median effect dose, because when f, + f, = 1.0,fJ, = f, = 0.5 and falfu = 1. Therefore, when y = 0, the y intercept occurs at log Din. Hence, Dm can be calculated from the antilog of (-y intercept/m). When the m and Dm values are determined by the median effect plot, the dose that is required to produce any level of effect can be calculated from equation 1. Synergy, summation (additivity), and antagonism of drug effects were quantitatively analyzed by the multiple-drug effect analysis developed by Chou and Talalay (5, 6) . The summation effects of the two drugs can be described by
, where (Da)1,2 is the effect of the mixture of drug 1 and drug 2 in a specified dose ratio.
When the median effect plots of each drug and their mixture are parallel (m1 = m2 = m1,2), then a mutually exclusive drug effect is indicated (e.g., similar mode of action), and in this case a = 0. When m1 = m2 but M1,2 is greater and upwardly concave, then a mutually nonexclusive drug effect is indicated (e.g., independent mode of action), and in this case a = 1. The interaction effect of two drugs was quantitatively determined by the combination index (C.I.), which is defined Computer programs based on the above equations have been used in the present studies for automated analysis of dose-effect data with an Apple II microcomputer or an IBM-PC (1) . The analysis quantifies synergy, summation, and antagonism effects at different effect levels. Relative potency, sigmoidicity of the dose-effect curves, regression coefficients, and graphics are also obtained from the computer analysis.
The application of this method is relatively simple. The experimental design requires that the ratio of the dose of the two drugs used in combination be kept constant and the dose of the mixture be varied. The experimental data obtained are logarithmically transformed, and the extreme points (f4 = 1 or 0) can be censored from the analysis since they cannot be transformed (log1o 0 = -oo). It is sometimes necessary to approximate mortality rates of 100% (e.g., 12 of 12 treated animals dead) to 96% (i.e., 11.5 of 12). With (92) 21 . The probability that the observed increase in survivor number or increase in mean time to death was due to chance is noted as follows: e, values and the other parameters shown in Table 2 for the single drug and the combination are calculated automatically. Statistical analyses. The LD90 for the virus was determined in a pilot study and estimated by the median effect plot. Survival data from the mouse studies were assessed with nonparametric tests as previously described (23) . The computation of P values took into account animals that died on or before day 21.
RESULTS
Single-drug treatment. Since PBS-treated mice inoculated with a low dose of virus first began to die 4 days later, we were obligated to start the various drug regimens after a 3-day delay ( Table 1 ). The mean day of death of the PBS-treated mice was 8.1 ± 2.2 (standard deviation [SDI), and the overall mortality rate in this group was 96%. For the drug-treated groups, the mortality rate was significantly lower at doses ranging from 10 nmol/kg per day for FMAU to 600 nmol/kg per day for ara-A. Although administration of FIAC, ara-A, or ACV, even at high doses (600 nmol/kg per day), failed to reduce mortality by more than one-half, less than 20 nmol of FMAU per kg was able to reduce mortality by two-thirds to three-quarters.
The estimated median effective dose was 22.5, 510, 901, and 7,587 nmol/kg per day for FMAU, FIAC, ara-A, and ACV, respectively (Table 2) , with a median effect dose ratio relative to FMAU of 1:23, 1:40, and 1:337 for FIAC, ara-A, and ACV, respectively. It was not possible to test ACV, ara-A, and FIAC at doses above 600 nmol/kg without encountering drug-related toxicity. The toxicity of the four drugs alone (and in combination) in uninfected mice, with the same dose scheduling, has been reported previously (22, 23) .
Combined treatment. Significant reduction in mortality compared with the controls and the single-drug treatment animals was noted for several doses of combinations (Table  1) . Because the slopes of the regression curves for the drugs alone and in combination were not parallel, the combination index was determined by using mutually nonexclusive assumptions (ot = 1), an analysis that yields a more conservative estimate of synergy. The median effective dose for the combinations at a ratio of 1:1 was 133, 376, and 550 nmol/kg per day for FIAC-ACV, FIAC-ara-A, and ACV-ara-A, respectively ( Table 2 ). For the combinations at a ratio of 1:8, the median effective dose was 60.3 and 65.2 nmol/kg per day for FMAU-ACV and FMAU-ara-A, respectively. In this type of analysis, the combination is treated as a third drug, and the contribution of FMAU to the median effective dose for the combination is only one-eighth that of ACV or ara-A.
When the survival data for the paired combinations of the four drugs were analyzed using the J, versus C.I. plot (see Materials and Methods), a strong synergistic interaction (C.I. < 1) was noted at different f, values ( Table 2) . As an example of how the survival analysis is performed, Fig. 1  and 2 show the dose-effect and J,,-C.I. plots for the combination of FMAU and ara-A (ratio, 1:8). The slope of the dose-effect curve (Fig. 1) for this combination was greater than for either drug alone, suggesting a mutually nonexclusive interaction. The J,-C.I. plot (Fig. 2) indicated that the C.I. value was less than 1 over the entire range ofJf, values, suggesting strong synergism at all effect levels.
As shown in Table 2 , the slopes (m values) of the median effect plots were steeper for the combinations than for the single drugs, except for ara-A. This change in the slope of the dose-effect curve (sigmoidicity), in conjunction with the lower than expected median effect (D,,,) values in combination, showed synergistic effects. For instance, in (5) . Conted isobolograms based on the median effect method ventional isobolograms do not use data efficiently, since an )u et al., in press) either in conventional form or in a isobol determines synergism-antagonism at one effect level vative version (Fig. 3) showed strong synergism for and is not applicable to mutually nonexclusive drugs, and ara-A. These results confirm the analyses obwhereas the method used in this report determines synerin thef,,-C.I. plot (Fig. 2) . When a drug ratio of 1:1 or gism-antagonism at all effect levels. The isobologram analythe combination of FMAU and ACV or ara-A was sis requires the construction of dose-effect curves for each doses ranging from 75 to 300 nmol/kg per day, less drug alone and for a series of mixtures of the drugs. The )% mortality was noted. The data (not shown) suggest doses of each drug alone and in combination that are ese combinations at high doses and different ratios are required to achieve an arbitrarily selected endpoint are then tagonistic.
used to construct the isobologram as a secondary plot. The lay 7 after virus inoculation, significant reduction in isobologram, which is a curve of equieffectiveness, reveals weight compared with the PBS-treated mice was by inspection whether the drug mixture displays antagonism, nt for all the single-drug treatment groups, except for summation (additivity), or synergism. An analysis based on [AU groups at doses greater than 10 nmol/kg. Most of the mutually nonexclusive equation should give a more wviving mice gradually gained weight, and by day 30 conservative estimation of synergism than the conventional irus inoculation their weights had increased by more isobologram (Fig. 3) , because the former has an additional Xo (range, 4 to 39%) compared with day 1 values (data term in calculating the value of C.I. (total, three terms). Dwn). A marked decrease in body weight was noted Therefore, the conventional isobolograms tend to overestimice treated with ara-A or ACV at doses of 600 mate synergism (C.I. has two terms). Figures 2 and 3 ;g. However, when these drugs were combined with (broken lines) should give identical conclusions because at the same dose, an increase in body weight was these plots are based on equation 3 ((x = 1) and are derived over that with each drug alone. The combination of from the same multiple-drug effect equation, except that the and ACV was not only the most synergistic, but at all f;-C.I. plot is effect-oriented and the isobologram is dosetested it was also the least toxic compared with the oriented. It should be noted, however, that thef,,-C.I. plot is Jrugs. Although the combination of ara-A and ACV at more convenient to use. From our experience with various nol/kg produced significant survival, a marked decombinations, isobolograms tend to jam the data points at in body weight was noted compared with that of the origin or at one axis. This causes difficulty in reading the s treated with 300 nmol/kg (Table 1) . With the exceppoints despite the fact that these isobolograms represent one combinations containing ara-A at the highest dose side of the same theory (Chou and Talalay, in press). The the toxicity of the different combinations did not conclusion that the summation of effects of two or more to be additive. The animals surviving the virus drugs can be calculated by multiplying the residual fraction ition were bled on day 30 to 32. All the animals were of the activity unaffected by each drug individually is based to have seroconverted.
on the view that two or more agents whose actions are totally independent of one another (and are therefore mutu-DISCUSSION ally nonexclusive) will each affect a constant fraction of a system. Although such a method of analysis has been widely e combination chemotherapy with antiviral drugs is used for combinations of anticancer drugs (29) does not take into account the shapes of the dose-effect curves. If the curve is hyperbolic for drug 1 and sigmoidal for drug 2, the fractional product method may yield erroneous conclusions. It has been shown from the derivation of equations that the fractional product method is valid if the following two conditions are satisfied: (i) each drug has a hyperbolic dose-effect curve (m = 1), and (ii) the effects of the two drugs are mutually nonexclusive (5).
As noted in Table 2 , the slopes of the dose-effect curves for ACV (0.27) and FIAC (0.5) were very shallow, and for FMAU (1.33) and ara-A (1.78) they were sigmoidal. Since all the m values are different from 1, the applicability of the fractional product method to the present study is ruled out. For all the combinations tested, a strong synergism was noted at effect levels of 0.5 to 0.9 ( Table 2) . The results obtained with the combination of FMAU and either ACV or ara-A (1:8 ratio) were very similar (slope = 1.8); however, the strongest synergy was noted for the combination of FIAC and ACV (1:1 ratio). For the combinations FMAU-ACV and FIAC-ACV, the slope of the dose-response curve was greater for the combination than for each drug alone (Table 2) .
In the present study, the survival data were interpreted for synergy, summation, or antagonism by computer analysis, as described previously (1, 5, 6) . This method of analysis is applicable to mutually exclusive and nonexclusive interactions. Usually the initial dose of each drug selected for a combination can be based on either the 50% effective dose (ED50) for each drug or on the level of drug in serum or the target organ (22) . The doses of the two drugs in combination are then varied upwards or downwards at a constant ratio. In more extensive studies, it may be necessary to test a different combination ratio (e.g., 1:2 or 2:1). This can be easily done, since it is not necessary to redetermine the median effective dose for each drug alone. Determination of the optimum drug ratio and schedule that will produce a synergistic effect over a wide range of affected fractions (fa) without increased toxicity is important. It should be noted that for chemotherapeutic drugs, only the high-effect region (.,-0.5) is of potential clinical relevance.
The reasons for the synergy observed with the combinations reported here may be related to the greater blockade of the viral DNA polymerase. The metabolites of the nucleosides described here are known to interact with the viral DNA polymerase (12, 16, 20, 24) . This enzyme, which is essential for HSV replication, is complex and contains various recognition sites. These (16) . The metabolism of FIAC is too complex to speculate at present on its interaction in combination with other antiviral agents at the DNA polymerse level (20) . The findings of additional studies on the levels of nucleotide pools in virus-infected and uninfected cells (e.g., Spector et al. [28] ) and the effect of dual inhibitors with purified viral DNA polymerase (e.g., Frank (Table 1 ). In general, the weights of the animals receiving the drug combinations were either higher than or similar to those of animals receiving single-drug therapy with the most toxic compound.
In conclusion, it appears from our analyses that all the combinations tested in this study are suitable for further investigation for clinical use. However, the toxicological profiles of these combinations and the optimum drug schedules will have to be ascertained before trials in humans with severe HSV infections are conducted.
